Insights for the Coming Financial Year
ANNOUNCEMENT NO. 272
ChemoMetec has revealed its financial forecast for the 2024/25 financial year, coinciding with the release of its annual report for 2023/24. This announcement sheds light on the company's anticipated performance and strategic direction in the marketplace.
Financial Projections for 2024/25
For the upcoming financial year, ChemoMetec predicts revenue in the range of DKK 435 million to DKK 450 million, which shows growth compared to the reported DKK 407.4 million for 2023/24. Additionally, the projected EBITDA for 2024/25 is set to be between DKK 216 million and DKK 223 million, an increase from the previous year's DKK 186.2 million.
Foundation of Their Strategy
The annual report provides a comprehensive overview of the reasoning behind these figures, crafted thoughtfully to take into account past performance and present market dynamics.
About ChemoMetec
Founded in 1997, ChemoMetec specializes in developing and marketing advanced instruments intended for cell counting and various essential measurements. Their products serve multiple industries, including pharmaceuticals, biotechnology, and agriculture. Recognized for their quality, ChemoMetec caters to a wide range of clients, including leading global pharmaceutical companies.
Contact Details for Leadership
If you have questions regarding the company's performance or forecasts, you're welcome to reach out to CEO Martin Helbo Behrens at (+45) 48 13 10 20, or CFO Kim Nicolajsen at the same number.
Advancements in Measurement Technology
ChemoMetec is dedicated to incorporating state-of-the-art technology into its offerings. Their instruments play a crucial role in pushing forward research and ensuring clients obtain precise and dependable results. As the demand for biotechnology solutions increases, ChemoMetec is well-positioned to strengthen its market presence.
Future Outlook
ChemoMetec's leadership is optimistic about prospects for the next financial year. With a strong emphasis on innovation and customer satisfaction, the company is well-equipped to seize emerging market opportunities and sustain its growth path.
Frequently Asked Questions
What revenue growth does ChemoMetec anticipate for 2024/25?
ChemoMetec expects its revenue to fall between DKK 435 million and DKK 450 million for the 2024/25 year, indicating a favorable growth trend compared to the previous year.
Who can I contact for more information about ChemoMetec?
For any inquiries, you can contact CEO Martin Helbo Behrens or CFO Kim Nicolajsen at (+45) 48 13 10 20.
When was ChemoMetec founded?
ChemoMetec was established in 1997 and has since become a prominent player in its industry.
What industries does ChemoMetec serve?
ChemoMetec's instruments are tailored for use across the pharmaceutical, biotechnology, and agricultural sectors globally.
How is ChemoMetec performing in the market?
ChemoMetec is experiencing revenue and EBITDA growth, reflecting its solid market performance and optimism for future achievements.